The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://emilywxjk770795.goabroadblog.com/37921296/glp-3-retatrutide-a-comparative-analysis